F. Tadiotto

Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.

A. Avogaro, G. Fadini, A. Lapolla, 2020, Metabolism: clinical and experimental.

Mechanisms of acute and chronic hypoglycemic action of gliclazide

A. Maran, M. Marescotti, A. Tiengo, 2000, Acta Diabetologica.

Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study.

A. Avogaro, G. Fadini, G. Targher, 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Effectiveness of dulaglutide in the real world and in special populations of type 2 diabetic patients.

A. Avogaro, G. Fadini, A. Lapolla, 2020, The Journal of clinical endocrinology and metabolism.

Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy

A. Avogaro, G. Fadini, A. Lapolla, 2019, Acta Diabetologica.

Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.

A. Avogaro, A. Lapolla, M. Rigato, 2021, Diabetes research and clinical practice.

Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study

L. Zenari, A. Lapolla, S. Lombardi, 2018, Diabetes Therapy.

Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.

A. Gallo, F. Piarulli, A. Pianta, 2015, Clinical therapeutics.

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study

A. Avogaro, G. Fadini, A. Lapolla, 2019, Diabetes, obesity & metabolism.